Literature DB >> 23852822

Congenital fibrinogen disorders: an update.

Philippe de Moerloose1, Alessandro Casini, Marguerite Neerman-Arbez.   

Abstract

Hereditary fibrinogen abnormalities comprise two classes of plasma fibrinogen defects: Type I, afibrinogenemia or hypofibrinogenemia, which has absent or low plasma fibrinogen antigen levels (quantitative fibrinogen deficiencies), and Type II, dysfibrinogenemia or hypodysfibrinogenemia, which shows normal or reduced antigen levels associated with disproportionately low functional activity (qualitative fibrinogen deficiencies). In afibrinogenemia and hypofibrinogenemia, most mutations of the FGA, FGB, or FGG fibrinogen encoding genes are null mutations. In some cases, missense or late truncating nonsense mutations allow synthesis of the corresponding fibrinogen chain but intracellular fibrinogen assembly and/or secretion are impaired. Afibrinogenemia is associated with mild-to-severe bleeding, whereas hypofibrinogenemia is most often asymptomatic. Thromboembolism may occur either spontaneously or in association with fibrinogen substitution therapy. Women with afibrinogenemia suffer from recurrent pregnancy loss but this can also occur in women with hypofibrinogenemia. Dysfibrinogenemia, caused mainly by missense mutations, is commonly associated with bleeding, thrombophilia, or both; however, most individuals are asymptomatic. Hypodysfibrinogenemia is a subcategory of this disorder. Even in specialized laboratories, the precise diagnosis of some fibrinogen disorders may be difficult. Determination of the molecular defects is important because it gives the possibility to confirm the diagnosis, to elaborate a diagnostic strategy, to distinguish in some cases that the patient is at risk of thrombosis rather than bleeding, and to enable prenatal diagnosis. However, genotype-phenotype correlations are not easy to establish. Replacement therapy is effective in treating bleeding episodes, but because the pharmacokinetics of fibrinogen after replacement therapy is highly variable among patients, it is important to adjust the treatment individually. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23852822     DOI: 10.1055/s-0033-1349222

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  60 in total

Review 1.  Fibrinogen and red blood cells in venous thrombosis.

Authors:  Maria M Aleman; Bethany L Walton; James R Byrnes; Alisa S Wolberg
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

2.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

3.  Sub-conjunctival Hemorrhage Following a Bout of Cough: A Harbinger of Underlying Bleeding Diathesis.

Authors:  Lakshmi Madhumathi Marimuthu; Raksha Ranjan; Venkatesh Chandrasekaran; Barath Jagadisan; Niranjan Biswal
Journal:  Indian J Pediatr       Date:  2017-04-25       Impact factor: 1.967

Review 4.  Thrombosis in Inherited Fibrinogen Disorders.

Authors:  Wolfgang Korte; Man-Chiu Poon; Alfonso Iorio; Michael Makris
Journal:  Transfus Med Hemother       Date:  2017-03-14       Impact factor: 3.747

Review 5.  What Is the Biological and Clinical Relevance of Fibrin?

Authors:  Rustem I Litvinov; John W Weisel
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

6.  Identification of novel mutations in patients with fibrinogen disorders and genotype/phenotype correlations.

Authors:  Elena Chinni; Giovanni Tiscia; Giovanni Favuzzi; Filomena Cappucci; Giuseppe Malcangi; Rossana Bagna; Claudia Izzi; Domenica Rizzi; Valerio De Stefano; Elvira Grandone
Journal:  Blood Transfus       Date:  2018-10-08       Impact factor: 3.443

7.  FGB and FGG derived from plasma exosomes as potential biomarkers to distinguish benign from malignant pulmonary nodules.

Authors:  Muyu Kuang; Yizhou Peng; Xiaoting Tao; Zilang Zhou; Hengyu Mao; Lingdun Zhuge; Yihua Sun; Huibiao Zhang
Journal:  Clin Exp Med       Date:  2019-10-01       Impact factor: 3.984

Review 8.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

9.  Targeted mutation of zebrafish fga models human congenital afibrinogenemia.

Authors:  Richard J Fish; Corinne Di Sanza; Marguerite Neerman-Arbez
Journal:  Blood       Date:  2014-02-19       Impact factor: 22.113

10.  Congenital fibrinogen disorders with repeated thrombosis.

Authors:  Xiuli Zhang; Chuang Zhang; Baoheng Wang; Ningheng Chen; Gaihe Sun; Xueli Guo
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.